Regulatory FDA experts endorse Moderna’s mRNA seasonal flu shot PharmaphorumA unanimous endorsement from FDA advisors brings Moderna's RNA-based seasonal influenza vaccine a step closer to US approval.Infectious DiseaseRead full story pharminent June 19, 2026 (Last updated: June 22, 2026) Pharmaphorum A unanimous endorsement from FDA advisors brings Moderna’s RNA-based seasonal influenza vaccine a step closer to US approval. Infectious Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA’s new voucher program hints at broader policy agenda, making many ‘uncomfortable’Next: Biogen to acquire RayThera for up to $1bn Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
